DEA’s latest marijuana rescheduling brief provides important supporting evidence for a key hemp policy principle: different compounds, products, doses and risks warrant different regulatory treatment.
Implications of the August 17, 2026 Government Post-Hearing Brief for Federal Hemp Policy and the Goodness of Hemp Act
Executive Summary
On August 17, 2026, the Department of Justice and Drug Enforcement Administration filed the Government’s post-hearing brief in the federal marijuana rescheduling proceeding.
The Government asks the Administrative Law Judge to recommend transferring marijuana, as defined in 21 U.S.C. § 802(16)(A), from Schedule I to Schedule III.
It does not seek descheduling or legalization. Instead, the Government argues that marijuana has a currently accepted medical use, accepted safety under medical supervision, and an abuse and dependence profile more consistent with Schedule III than Schedule I or II.
For the hemp industry, the most significant portions of the filing are not the scheduling recommendation itself, but the Government’s scientific and regulatory distinctions among THC, CBD, naturally occurring cannabinoids, dose, product form, testing and quality controls.
Those findings reinforce the need for a federal framework that distinguishes industrial hemp from cannabinoid consumer products, and non-intoxicating cannabinoids from intoxicating THC products.
KEY POLICY POINT: The Government’s own analysis does not treat all cannabinoids alike. It identifies Δ9-THC as the principal intoxicating cannabinoid responsible for abuse potential while describing CBD as having negligible abuse potential.
Findings Most Relevant to Hemp
1. DEA/HHS Expressly Distinguish Intoxicating THC From CBD
The brief states that Δ9-THC is the major psychoactive and intoxicating cannabinoid in marijuana and is primarily responsible for marijuana’s abuse potential.
In contrast, it states that CBD has negligible abuse potential.
This is an important federal acknowledgment that cannabinoids should not be treated as pharmacologically equivalent merely because they originate in Cannabis sativa.
Policy significance: This supports a risk- and use-based framework that separates industrial hemp, non-intoxicating cannabinoid products and intoxicating THC products rather than collapsing all three into a single regulatory category.
2. The Filing Contains Important Language Regarding Naturally Occurring Δ8-THC
The Government recognizes that both Δ9-THC and Δ8-THC can produce psychoactive effects, but notes that only small quantities of Δ8-THC are found naturally in the plant.
The brief does not itself recommend prohibiting converted or manufactured Δ8 products, and NHA should not attribute that conclusion to DEA.
However, the finding is highly relevant to current legislative efforts that distinguish cannabinoids naturally present in commercially meaningful quantities from intoxicants produced through conversion or synthesis.
3. Cannabis sativa Is Treated as a Complex Plant — Not as a Synonym for THC
The filing describes Cannabis sativa L. as a highly polymorphic plant containing more than 550 identified compounds, including cannabinoids, terpenoids, flavonoids, fatty acids, sugars, amino acids and proteins.
It notes that nearly 200 cannabinoids have been identified.
For industrial hemp policy, this reinforces the basic point that the agricultural plant and its many lawful industrial, food, feed and material uses should not be regulated solely through the lens of intoxicating THC.
4. Dose, Concentration and Route of Administration Matter
The Government’s evidence repeatedly describes marijuana effects as dose-dependent and recognizes that route of administration changes onset and intensity.
Higher doses and faster delivery can produce more intense effects and a greater likelihood of negative subjective effects.
This supports regulating finished cannabinoid products according to intoxicating potential, dose, concentration, serving size and intended use — not simply according to whether the starting material met the statutory definition of hemp.
5. Product Testing, Labeling and Manufacturing Controls Are Treated as Material Safeguards
The brief emphasizes variability in botanical products arising from growing conditions, harvest, processing, handling, transportation and testing, and identifies safety, quality and consistency concerns where unified controls are absent.
It also discusses state medical systems using certified laboratories, certificates of analysis, THC/CBD concentration information, warning labels and regulated dispensing.
Policy significance: This weighs strongly in favor of a legitimate federal consumer-product framework for cannabinoids — including manufacturing standards, testing, labeling, serving-size controls, child-resistant protections where appropriate and accountable market participants — rather than either an unregulated marketplace or a blanket prohibition.
6. FDA’s Scientific Role Is Central to the Government’s Case
FDA’s scientific and medical evaluation supplies much of the foundation for the Government’s position.
The brief relies on FDA’s assessment of pharmacology, abuse potential, medical use, adverse events and safety, and references approved cannabinoid-related drug products.
This reinforces the principle that FDA is the appropriate federal scientific and consumer-health authority for legitimate non-intoxicating cannabinoid products, while DEA remains focused on controlled-substance status.
What the Brief Does — and Does Not — Do to Hemp
- It does not place hemp, CBD, hemp grain, hemp fiber or hemp-derived products into Schedule III. The proceeding expressly concerns marijuana as defined in 21 U.S.C. § 802(16)(A).
- It does not deschedule marijuana. DOJ/DEA argue that marijuana should remain a controlled substance, but at Schedule III.
- It does not endorse an unregulated intoxicating-cannabinoid marketplace. The Government accepts that marijuana presents public-health, workplace, transportation and enforcement concerns even while concluding that Schedule I is no longer appropriate.
- It does provide federal scientific findings that can inform the hemp debate: CBD and THC have materially different abuse profiles; Δ8 exists naturally only in small quantities; dose and route matter; and product quality controls matter.
Implications for the Goodness of Hemp Act
The Government’s reasoning is broadly consistent with the architecture NHA has advocated through the Goodness of Hemp Act: regulate according to risk, intended use and product characteristics; protect true industrial hemp; preserve lawful non-intoxicating cannabinoids; close pathways that allow synthetic or converted intoxicants to masquerade as ordinary hemp; and establish accountable federal lanes for legitimate consumer products.
The Government’s brief does not address or endorse the Goodness of Hemp Act. NHA cites these findings as supporting evidence for the broader principle that different compounds, products, doses and risks warrant different regulatory treatment.
Protect the Industrial Hemp Lane
The rescheduling case is about intoxicating marijuana, not fiber, grain, seed, food, feed, construction materials or other industrial applications.
NHA should continue insisting that agricultural hemp be clearly separated from cannabinoid-product policy wherever possible.
Preserve a Legitimate Non-Intoxicating Cannabinoid Lane
DEA/HHS’s explicit treatment of CBD as having negligible abuse potential is a useful federal finding supporting proportionate treatment of non-intoxicating cannabinoids rather than subjecting them to rules designed for intoxicating THC.
Use “Commercially Meaningful Natural Occurrence” as a Defensible Dividing Concept
The Government’s observation that naturally occurring Δ8 is present only in small quantities strengthens the factual basis for distinguishing natural plant constituents from high-potency intoxicants produced by conversion or synthesis.
Regulate Intoxicating Products as Products
Dose, concentration, route of administration, testing, labeling and product consistency are central to the Government’s analysis.
These are the same variables Congress should address when creating a durable federal pathway for intoxicating hemp beverages or other finished products.
Keep FDA and Other Appropriate Regulators in Their Proper Lanes
The filing demonstrates that cannabinoid policy is not solely a DEA matter.
A comprehensive framework should assign agricultural production to USDA, consumer-health and non-intoxicating cannabinoid issues to FDA, and any lawful beverage pathway to the regulator Congress determines is best suited for alcohol-style product oversight.
Recommended NHA Messaging
NHA should avoid portraying this filing as a hemp victory or as federal legalization of cannabis.
The stronger and more accurate message is that the federal government is itself moving toward a more differentiated, evidence-based treatment of cannabis and cannabinoids.
Congress should apply the same discipline to hemp.
Conclusion
The August 17 Government brief gives NHA a useful new federal record from which to argue for comprehensive hemp reform.
Its strongest value is not Schedule III itself.
Its value is the Government’s acknowledgment that cannabinoids differ, that intoxicating effects are principally tied to THC, that CBD has negligible abuse potential, that naturally occurring Δ8 exists only in small quantities, and that dose, manufacturing, testing and labeling all influence risk.
Those findings support a durable federal policy that protects farmers and industrial hemp markets, creates a lawful pathway for legitimate non-intoxicating cannabinoid products, and prevents chemically converted intoxicants from relying on the word “hemp” as a substitute for appropriate regulation.
That is the policy space in which the Goodness of Hemp Act should continue to be positioned.
“The lesson for hemp is not that everything derived from cannabis should be treated the same. The lesson is exactly the opposite: risk, intoxication, dose, intended use and product controls matter. Federal hemp law should reflect those distinctions.”
LEARN MORE ABOUT THE GOODNESS OF HEMP ACT →
Read the Source Documents
U.S. Department of Justice, Drug Enforcement Administration
Government’s Post-Hearing Brief
DEA Docket No. 1362 / Hearing Docket No. 26-96
Filed August 17, 2026